Christian J. Hendriksz
The Mark Holland Metabolic Unit NW2, Salford Royal NHS Foundation Trust, Salford, United KingdomSalford Royal NHS Foundation TrustUnited KingdomSalford, United KingdomThe Mark Holland Metabolic Unit NW2, Salford Royal NHS Foundation Trust, Salford, United Kingdom
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Joseph Muenzer
Department of Pediatrics, Division of Genetics and Metabolism, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAUniversity of North Carolina at Chapel HillUSAChapel Hill, NC, USADepartment of Pediatrics, Division of Genetics and Metabolism, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Barbara K. Burton
Division of Genetics, Birth Defects and Metabolism, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, USAnn & Robert H. Lurie Children’s HospitalUSChicago, IL, USDivision of Genetics, Birth Defects and Metabolism, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, US
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Luying Pan
Shire, Lexington, MA, USAShireUSALexington, MA, USAShire, Lexington, MA, USA
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Nan Wang
Shire, Lexington, MA, USAShireUSALexington, MA, USAShire, Lexington, MA, USA
Hicham Naimy
Shire, Lexington, MA, USAShireUSALexington, MA, USAShire, Lexington, MA, USA
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Arian Pano
Shire, Lexington, MA, USAShireUSALexington, MA, USAShire, Lexington, MA, USA
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.
Ann J. Barbier
Shire, Lexington, MA, USAShireUSALexington, MA, USAShire, Lexington, MA, USA
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian J. Hendriksz received consulting fees from Actelion Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Shire, and Sanofi-Genzyme and contracted research with Actelion Pharmaceuticals, BioMarin Pharmaceutical, Amicus Therapeutics, GlaxoSmithKline, Shire, Sanofi-Genzyme, and Synageva BioPharma. Joseph Muenzer is a consultant to Shire, Janssen R&D, Green Cross, and PTC Therapeutics and serves on advisory boards and speaker’s bureaus for Genzyme, BioMarin, and Shire. He is currently the principal investigator for phase 1/2 and phase 2/3 intrathecal enzyme replacement clinical trials for MPS II sponsored by Shire. Barbara K. Burton received consulting fees from, and serves on advisory boards for, BioMarin and Shire and contracted research for BioMarin, Cytonet, Genzyme, Shire, Synageva, and Ultragenyx. Luying Pan, Nan Wang, Hicham Naimy, and Arian Pano are all employees of, and own stock in, Shire. Ann J. Barbier, at the time of the study, was an employee of Shire and owns Shire stock.